Biotechnology US healthcare giant Johnson & Johnson’s subsidiary Janssen says that the European Commission has granted marketing authorization for Tremfya (guselkumab), alone or in combination with methotrexate (MTX), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. 1 December 2020